AI wearables move closer to pulmonary and sleep medicine
AI-enabled wearables are moving closer to routine use in pulmonary and sleep medicine. The shift follows updated FDA guidance in early 2026 that sought to ease regulation for some wearable devices, body-worn sensors and clinical decision support software. The technology is being positioned as a way to support proactive care, continuous monitoring and more individualized treatment decisions.
The devices are evolving beyond simple consumer trackers. Researchers are pairing sweat-based biomarker platforms, electrochemical sensors for bodily fluids, exhaled-breath analysis, photoplethysmography, ECG and acoustic sensors with machine-learning software that can combine signals from multiple sources. In respiratory care, the target uses include COPD flare monitoring, nitric oxide assessment for respiratory distress, cough and wheeze detection, and home-based evaluation of obstructive sleep apnea risk.
More than 200 sensor-based digital health technology devices have been authorized for marketing in the United States since 2014. But clinical adoption still depends on proof that the data are accurate, relevant and actionable. Sensor outputs may need to be paired with established measures such as spirometry, biopsy findings or validated questionnaires, while AI models must be tested in adequately powered clinical studies with sufficient sample sizes, diverse populations and, where possible, multicenter designs.
Sleep medicine is emerging as one of the fastest-moving areas because several wearable home sleep apnea testing devices and software-as-a-medical-device products have been cleared for diagnosis or risk assessment. Their appeal is clear: automated scoring, limited setup, fewer wires and the ability to collect data across multiple nights. If developers, clinicians, engineers, data scientists and regulators can resolve persistent issues in validation, reimbursement, interoperability, cybersecurity and equitable performance, AI wearables could become a practical clinical layer for earlier detection, better follow-up and more efficient management of chronic respiratory disease.